Page 96 - Drug Class Review
P. 96
Page 78 of 205
Drug Effectiveness Review Project
placebo 71 55 99% 1% 20
donepezil 10 mg 72 57 99% 1% 20 Secondary Outcome Measures: CDR-SB; patient rated quality of life (scale not specified but reported Timing of assessments: Baseline and weeks 6, 12, 18, 24 and 30 (endpoint = 24 weeks; placebo washout phase = 30 weeks; outcome measures reported for 24 weeks) No significant differences in quality of life scores at any time during the study; authors note significant variability in scale scores and inherent problems with measurement Mean improvement in IDDD total score and self-care score NR; statistically significant improvement in
Alzheimer classification: Mild to moderate
Groups similar at baseline: Yes
donepezil 5 mg 72 61 100% <1% 20 Primary Outcome Measures: ADAS-Cog; CIBIC-plus in Rogers et al., 1998); modified IDDD Health Outcome Measures: mg/d Intermediate Outcome Measures:
• • • • •
Final Report Update 1 Authors: Burns et al. Year: 1999 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Other • Other germane population qualities: Baseline mean MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
